Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
IL5-H52H8 | Human | Human IL-15 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
IL5-M5255 | Mouse | Mouse IL-15 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
IL5-H82F3 | Human | Biotinylated Human IL-15 Protein, Fc,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
IL5-M82F3 | Mouse | Biotinylated Mouse IL-15 Protein, Fc,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
IL5-H4117 | Human | Human IL-15 Protein, Tag Free (SPR verified) | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
Biotinylated Mouse IL-15, Fc,Avitag (Cat. No. IL5-M82F3) stimulates proliferation of CTLL-2 cells. The ED50 for this effect is 0.531-1.999 μg/mL (Routinely tested).
Human IL-2 R beta, Fc Tag (SPR verified) (Cat. No. ILB-H5253) captured on CM5 chip via anti-human IgG Fc antibody, can bind Human IL-15, Tag Free (Cat. No. IL5-H4117) with an affinity constant of 9.5 nM as determined in a SPR assay (Biacore T200) (QC tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
OXS-C3550 | OXS-3350; OXS-C3550 | Preclinical | University of Minnesota, GT Biopharma | Acute myeloid Leukemia (AML) | Details |
Humanized mik-beta-1 mAb (National Cancer Institute) | Hu-mik-beta-1 | Phase Ⅰ | National Cancer Institute | Celiac disease | Details |
BJ-001 | BJ-001 | Phase Ⅰ | BJ Bioscience | Solid tumours, Infectious disease | Details |
SHR-1501 | SHR-1501,SHR1501 | Phase Ⅰ | Jiangsu Hengrui Medicine | Malignancies | Details |
Anti-interleukin-15-vaccine (CIGB) | CIGB-50 | Phase Ⅰ | Center for Genetic Engineering and Biotechnology, Heber Biotech | Rheumatoid arthritis (RA) | Details |
AMG-714 | AMG-714; HuMab-IL15; PRV-015 | Phase Ⅱ | Genmab, Amgen, Celimmune, Provention Bio | Celiac disease | Details |
XmAb24306 | XmAb-24306,XmAb24306 | Phase Ⅰ | Xencor, Roche | Solid tumors | Details |
This web search service is supported by Google Inc.